Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “immunotherapy”

175 pharma patents match "immunotherapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 175
Index total 30,257
Page 3 / 8

Quick answer

This filtered view shows 175 pharmaceutical patents matching "immunotherapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

175 results for “immunotherapy” · 30,257 patents in full index Clear search

  1. US 11504426

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  2. US 11497770

    Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy

    The Regents of the University of Colorado · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted

  3. US 11497713

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted

  4. US 11485788

    Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2022 · Expires Oct 27, 2042

    granted

  5. US 11464801

    Compositions and methods for treating cancer with anti-CD33 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted

  6. US 11453719

    Compositions and methods for treating cancer with anti-ROR1 immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 27, 2022 · Expires Sep 22, 2042

    granted

  7. US 11446332

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted

  8. US 11439632

    Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

    Northwestern University · Granted Sep 13, 2022 · Expires Sep 8, 2042

    granted

  9. US 11433143

    Nano-enabled immunotherapy in cancer

    The Regents of the University of California · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted

  10. US 11419898

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted

  11. US 11389480

    Human monoclonal antibody targeting TNFR2 for cancer immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted

  12. US 11384337

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted

  13. US 11376324

    Sting activating nanovaccine for immunotherapy

    The Board of Regents of the University of Texas System · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted

  14. US 11357842

    PD-L1 targeting DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted

  15. US 11344579

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 31, 2022 · Expires May 26, 2042

    granted

  16. US 11337998

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 24, 2022 · Expires May 19, 2042

    granted

  17. US 11324813

    Indoleamine 2,3-dioxygenase based immunotherapy

    IO Biotech ApS · Granted May 10, 2022 · Expires May 5, 2042

    granted

  18. US 11304979

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

  19. US 11304996

    Yeast-based immunotherapy and type I interferon sensitivity

    The Regents of the University of Colorado, a Body Corporate · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

  20. US 11291687

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted

  21. US 11285194

    Combination immunotherapy approach for treatment of cancer

    Calidi Biotherapeutics, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted

  22. US 11278592

    Methods and compositions for TUSC2 immunotherapy

    The Board of Regents of the University of Texas System · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  23. US 11273181

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  24. US 11273180

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.